Literature DB >> 7178190

A tethering system for intravenous and intragastric drug administration in the baboon.

S E Lukas, R R Griffiths, L D Bradford, J V Brady, L Daley.   

Abstract

A system for minimally restraining adult baboons with chronic intravenous (IV) or intragastric (IG) catheters for long term pharmacological and behavioral studies is described. The system consists of an adjustable foam-padded backplate and harness which is custom-fitted to each animal. A flexible stainless-steel cable connects the backplate to a liquid swivel through which the drugs are administered. Methods for the preparation and surgical implantation of IV and IG catheters are also described. Intravenous catheters were sequentially implanted in the internal jugular, femoral, axillary and external jugular veins. Catheters have remained patent for as long as 45 months, and catheter life appears to be conjointly determined by both site and number of successive implantations. The advantages of the harness/tether system over previously used chair-restraint procedures include greater freedom of movement, fewer restraint-related health problems, and longer experimental life of the animals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7178190     DOI: 10.1016/0091-3057(82)90366-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  18 in total

1.  D-Amino-Acid Oxidase Inhibition Increases D-Serine Plasma Levels in Mouse But not in Monkey or Dog.

Authors:  Camilo Rojas; Jesse Alt; Nancy A Ator; Ajit G Thomas; Ying Wu; Niyada Hin; Krystyna Wozniak; Dana Ferraris; Rana Rais; Takashi Tsukamoto; Barbara S Slusher
Journal:  Neuropsychopharmacology       Date:  2015-10-16       Impact factor: 7.853

2.  Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.

Authors:  Amy K Goodwin; Roland R Griffiths; P Rand Brown; Wolfgang Froestl; Cornelis Jakobs; K Michael Gibson; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2006-09-20       Impact factor: 4.530

3.  Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons.

Authors:  R R Griffiths; R J Lamb; C A Sannerud; N A Ator; J V Brady
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons.

Authors:  Amy K Goodwin; Wolfgang Froestl; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2005-03-01       Impact factor: 4.530

5.  Development of a novel alcohol and nicotine concurrent access (ANCA) self-administration procedure in baboons.

Authors:  August F Holtyn; Catherine M Davis; Elise M Weerts
Journal:  Drug Alcohol Depend       Date:  2019-11-11       Impact factor: 4.492

6.  Intravenous self-administration of γ-hydroxybutyrate (GHB) in baboons.

Authors:  Amy K Goodwin; Barbara J Kaminski; Roland R Griffiths; Nancy A Ator; Elise M Weerts
Journal:  Drug Alcohol Depend       Date:  2010-11-26       Impact factor: 4.492

7.  Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): time course and severity of withdrawal in baboons.

Authors:  Amy K Goodwin; K Michael Gibson; Elise M Weerts
Journal:  Drug Alcohol Depend       Date:  2013-03-26       Impact factor: 4.492

8.  Phencyclidine-analogue self-injection by the baboon.

Authors:  S E Lukas; R R Griffiths; J V Brady; R M Wurster
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.

Authors:  Nancy A Ator; John R Atack; Richard J Hargreaves; H Donald Burns; Gerard R Dawson
Journal:  J Pharmacol Exp Ther       Date:  2009-09-29       Impact factor: 4.030

10.  Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon.

Authors:  R J Lamb; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.